{"title":"临床补充:多发性硬化症-临床图片和治疗策略","authors":"H. Lins","doi":"10.1002/SITA.200400056","DOIUrl":null,"url":null,"abstract":"Multiple Sclerosis is a chronic inflammatory disorder of the central nervous system, affecting up to 1.5 % of the population in the US, UK, or Germany. Various subtypes exhibit different patterns of myelin or axonal damage and different stages of inflammation and neurodegeneration. The clinical pictures vary from rare attacks to chronically progressive disability. Current treatment options are mainly immunosuppressive or immunomodulatory [1].","PeriodicalId":88702,"journal":{"name":"Signal transduction","volume":"42 2","pages":"266-272"},"PeriodicalIF":0.0000,"publicationDate":"2005-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/SITA.200400056","citationCount":"0","resultStr":"{\"title\":\"Clinical Add‐on: Multiple sclerosis – clinical picture and therapeutic strategies\",\"authors\":\"H. Lins\",\"doi\":\"10.1002/SITA.200400056\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Multiple Sclerosis is a chronic inflammatory disorder of the central nervous system, affecting up to 1.5 % of the population in the US, UK, or Germany. Various subtypes exhibit different patterns of myelin or axonal damage and different stages of inflammation and neurodegeneration. The clinical pictures vary from rare attacks to chronically progressive disability. Current treatment options are mainly immunosuppressive or immunomodulatory [1].\",\"PeriodicalId\":88702,\"journal\":{\"name\":\"Signal transduction\",\"volume\":\"42 2\",\"pages\":\"266-272\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/SITA.200400056\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Signal transduction\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/SITA.200400056\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Signal transduction","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/SITA.200400056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Clinical Add‐on: Multiple sclerosis – clinical picture and therapeutic strategies
Multiple Sclerosis is a chronic inflammatory disorder of the central nervous system, affecting up to 1.5 % of the population in the US, UK, or Germany. Various subtypes exhibit different patterns of myelin or axonal damage and different stages of inflammation and neurodegeneration. The clinical pictures vary from rare attacks to chronically progressive disability. Current treatment options are mainly immunosuppressive or immunomodulatory [1].